The biotech company PharmaInformatic has developed an extensive knowledge database on oral bioavailability of drugs that allows the targeted development of new drugs on the computer.
The winners of the first LUSH prize for replacement of animal use originated by the cosmetic manufacturer LUSH in cooperation with the British organization Ethical Consumers are determined. This year there are 13 prize winners in five distinct categories.
The European Coalition to End Animal Experiments (ECEAE) has welcomed the position of Mr Tonio Borg, Commissioner Designate for the Health and Consumer Affairs portfolio, on the need for the Cosmetics Directive marketing ban to come into force in March 2013.
American and Korean scientists have created a human disease model-on-a-chip that mimics pulmonary edema using a biomimetic microdevice that reconstitutes organ-level lung functions.
Scientists from the Department of Pharmacy at the Saarland University and the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) have developed a drug-delivery system that looks like a corn cob.
A team of scientists have been successfully in cultivating stem cells from human heart muscle tissue that can contract just as strong as natural tissue.
Prof. Hans Schöler´s team from the Max Planck Institute (MPI) for Molecular Biomedicine in Münster have developed a stem cell-based technique for the neurodegenerative disease amyotrophic lateral sclerosis (ALS).
A German research team has analyzed 4,000 blood samples, which derived from different research projects. In so-called metabolome analysis they identified 14 novel biomarkers for type 2 diabetes.
Researchers from Helmholtz Zentrum München have converted glial cells (supporting cells) directly into functional nerve cells, which play normally an important role in wound healing and information processing of neurons.
The chemical company BASF SE has provided U.S. based Institute for In Vitro Sciences (IIVS) with equipment critical to replacing the use of animals for eye irritation testing of certain chemicals. IIVS will place the units at each of its newly developed training laboratories in Xi'an, Beijing, and Guangzhou, China.